Regulated information

Mastaplex and Vetoquinol announce distribution agreement

Mastaplex Ltd (New Zealand, unlisted) and Vetoquinol (VETO: France Euronext) are pleased to announce an extension of their exclusive distribution agreement for Mastatest..

Rapport financier semestriel 2022 (french)

Rapport financier semestriel 2022 (french)

Growth driven by innovation

Ever since the company was founded in 1933, innovation has been a major component of Vetoquinol's development strategy.

3rd generation appointed chairman of the board of directors of VETOQUINOL SA

At the Combined General Meeting it was also announced that Mr. Etienne Frechin will resign as Chairman of the Board of Vetoquinol, effective 1st July 2023. Mr. Etienne Frechin will remain a Director of the company, hence continuing to share his broad experience. On 25 May 2023, the Board of Directors appointed Mr. Matthieu Frechin, Chief Executive Officer of the Group, as Chairman of the Board of Directors of Vetoquinol effective 1st July 2023.

Universal registration document 2022

Universal Registration Document including the Annual Financial Report

Essential products

Essential products for the most common needs

Worlds Top 10

The animal health company is firmly established in the world's Top 10. 

Q1 2023 Sales: €145M

Vetoquinol recorded sales of €145 million for the first three months of the 2023 financial year, up 7.7% on a reported basis and 7.2% at constant exchange rates.

Document d’enregistrement universel (URD) 2022 version XBRL

Document d'enregistrement universel 2022 incluant le rapport financier annuel

Availability of the 2022 universal registration document

On 13 April 2023, Vetoquinol filed its 2022 Universal Registration Document with the Autorité des Marchés Financiers (AMF) in ESEF (European Single Electronic Format).